OMERACT systemic lupus erythematosus domain survey
Wils Nielsen,Vibeke Strand,Lee Simon,Ellie Pinsker,Dennisse Bonilla,Eric Morand,Julian Thumboo,Martin Aringer,Marta Mosca,Ian Bruce,Ioannis Parodis,Alfred Kim,Maya Desai,Yvonne Enman,Beverley Shea,Daniel J Wallace,Yashaar Chaichian,Sandra Navarra,Cynthia Aranow,Meggan Mackay,Kimberly Trotter,Oshrat E Tayer-Shifman,Alí Duarte-García,Lai Shan Tam,Manuel F Ugarte-Gil,Guillermo J Pons-Estel,John A Reynolds,Mandana Nikpour,Alberta Hoi,Juanita Romero-Diaz,Amita Aggarwal,Chi Chiu Mok,Keishi Fujio,Rosalind Ramsey-Goldman,Dafna D Gladman,Laurent Arnaud,Irene E M Bultink,Guillermo Ruiz-Irastorza,Luís Sousa Inês,Simone Appenzeller,Chrisanna Dobrowolski,Ann Elaine Clarke,Diane L Kamen,Michelle Barraclough,Chiara Tani,Jose A Gómez-Puerta,Victoria P Werth,Patti Katz,Behdin Nowrouzi-Kia,Sindhu R Johnson,Aaron M Drucker,Zahi Touma,OMERACT SLE Working Group
DOI: https://doi.org/10.1016/j.semarthrit.2024.152520
Abstract:Background: Since the development of the OMERACT Systemic Lupus Erythematosus (SLE) Core Outcome Set (COS) in 1998, many new SLE domains have been identified and measures developed, creating a need to update the SLE COS. To revisit the 1998 SLE COS and research agenda domains, and generate new candidate domains, we conducted this study of patients with SLE and collaborators. Objective: (1) To evaluate existing candidate SLE domains for inclusion in the SLE COS. (2) To generate additional candidate SLE domains for COS consideration. (3) To engage SLE collaborators, including patients, in developing the updated SLE COS. Methods: The OMERACT SLE Working Group's steering committee developed a survey to assess the importance of candidate SLE domains and generate additional domains for consideration towards the SLE COS. Patients with SLE followed at the University of Toronto Lupus Clinic (patient group) and members of the OMERACT SLE Working Group (collaborator group) were invited to complete the survey between August 2022 and February 2023. Results: A total of 175 patients were invited and 100 completed the survey. Of 178 collaborators invited, 145 completed the survey. Patients tended to prioritize life-impact domains while collaborators prioritized clinical domains. Both patients and collaborators recommended additional domains to those included in the 1998 SLE COS and research agenda. Conclusion: The domain inclusion and importance results demonstrate that patients and collaborators prioritize different domains, so capturing the perspectives of both groups is essential to ensure a holistic assessment of SLE. The results of the study identify domains that already have a high level of agreement for potential inclusion in the SLE COS, domains that require further explanation, and novel domains that warrant consideration.